Surgical Options and Orthopedic Oncology for TGCT
At a Glance
Surgery is the primary treatment for Tenosynovial Giant Cell Tumor (TGCT), but outcomes depend heavily on the subtype and surgical expertise. It is highly recommended to seek an orthopedic oncologist who can determine whether an open, arthroscopic, or combined synovectomy is best for your joint.
Surgery is the primary treatment for Tenosynovial Giant Cell Tumor (TGCT), but the complexity of the operation depends entirely on your subtype. Because this is a rare tumor that can weave itself into the vital structures of your joint, the expertise of your surgeon is one of the most critical factors in your long-term outcome [1][2].
Choosing the Right Surgeon
It is highly recommended that patients with TGCT—especially the diffuse subtype—seek care from an orthopedic oncologist rather than a general orthopedic surgeon [2][3].
- General Orthopedic Surgeons typically focus on common mechanical issues like sports injuries or joint replacements.
- Orthopedic Oncologists are specifically trained to treat rare tumors of the bone and soft tissue. They understand the locally aggressive nature of TGCT and have the specialized skills needed to perform a meticulous resection—a precise removal of tumor tissue while preserving as much healthy joint function as possible [4][1].
Surgical Approaches: Localized vs. Diffuse
The goal of surgery changes based on how the tumor grows:
- Localized TGCT (L-TGCT): The surgeon typically performs a marginal excision [5]. Because the tumor is a discrete nodule, the surgeon can usually remove it entirely while achieving clear margins. A clear margin means that the outer rim of the removed tissue is entirely healthy, indicating that no microscopic tumor cells were left behind at the edges [5][6].
- Diffuse TGCT (D-TGCT): The surgeon must perform a synovectomy, which involves removing the diseased lining of the joint (synovium) [1][4].
The Debate: Open vs. Arthroscopic
For diffuse disease, there is no single “best” way to operate. Your surgeon will choose an approach based on where the tumor is located:
- Arthroscopic Synovectomy: The surgeon uses small incisions and a camera (arthroscope) to remove the tumor. This allows for a faster recovery and less joint stiffness [7]. However, it can be difficult to reach every nook and cranny of a complex joint using only a camera [4].
- Open Synovectomy: The surgeon makes a larger incision to see the entire joint directly. This is often necessary for tumors that have grown into difficult-to-reach areas, such as the back of the knee (the popliteal space) [4][8].
- Combined Approach: Many experts now use both techniques in a single surgery to ensure they clear the tumor from both the front and back of the joint [7][9].
The Reality of Recurrence
Even with the best surgeon, diffuse TGCT is notoriously difficult to cure through surgery alone. Because the tumor is infiltrative—growing like moss into the surrounding tissue—microscopic bits of the tumor can be left behind [1][7]. These invisible remnants are why recurrence rates for diffuse disease remain high, often requiring long-term monitoring with MRIs [1][10].
If a complete removal is too risky because the tumor is wrapped around a nerve or major blood vessel, your surgeon may perform a subtotal synovectomy (removing most but not all of the tumor) [4].
Radiotherapy as an Option
In cases where diffuse TGCT is repeatedly returning or impossible to clear with surgery alone, your care team may discuss radiotherapy [11]. Radiation—either delivered externally or via an isotope injected directly into the joint space (intra-articular radiotherapy)—can act as an adjuvant treatment to help kill microscopic tumor cells left behind after surgery. While not used for everyone, it is a well-established option for stubborn, refractory disease [11][12].
Common questions in this guide
Why should I see an orthopedic oncologist for TGCT surgery?
What is the difference between open and arthroscopic synovectomy?
Can surgery completely cure TGCT?
What happens if my surgeon cannot remove the entire tumor?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Are you an orthopedic oncologist, and how many diffuse-type TGCT surgeries have you performed this year?
- 2.Given the location of my tumor, do you recommend an open, arthroscopic, or combined surgical approach?
- 3.What is your plan for achieving clear margins, and what happens if you cannot safely remove the entire tumor?
- 4.Will we be using a multidisciplinary tumor board to review my case and plan the surgery?
- 5.How will this surgery affect my long-term joint function and the risk of developing secondary osteoarthritis?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (12)
- 1
Surgical management of 144 diffuse-type TGCT patients in a single institution: A 20-year cohort study.
Spierenburg G, van der Heijden L, Mastboom MJL, et al.
Journal of surgical oncology 2022; (126(6)):1087-1095 doi:10.1002/jso.26991.
PMID: 35736790 - 2
Current management of Tenosynovial Giant Cell Tumours of the knee in the United Kingdom.
Ward TRW, Ashford RU, Eastley NC
The Knee 2025; (56()):407-414 doi:10.1016/j.knee.2025.06.006.
PMID: 40618551 - 3
Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease.
Healey JH, Bernthal NM, van de Sande M
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews 2020; (4(11)):e20.00028 doi:10.5435/JAAOSGlobal-D-20-00028.
PMID: 33156160 - 4
Lowering the recurrence rate in pigmented villonodular synovitis: A series of 120 resections.
Capellen CF, Tiling R, Klein A, et al.
Rheumatology (Oxford, England) 2018; (57(8)):1448-1452 doi:10.1093/rheumatology/key133.
PMID: 29788491 - 5
Demystifying Giant Cell Tumours of Tendon Sheath (GCTTS): A Case Series of 18 Cases with Review of Literature.
Khurana A, Singh JP, Preeti , et al.
Indian journal of orthopaedics 2023; (57(11)):1858-1873 doi:10.1007/s43465-023-00990-8.
PMID: 37881282 - 6
Giant cell tumour of tendon sheath and synovial membrane: A review of 26 cases.
Kant KS, Manav AK, Kumar R, et al.
Journal of clinical orthopaedics and trauma 2017; (8(Suppl 2)):S96-S99 doi:10.1016/j.jcot.2017.06.014.
PMID: 29339850 - 7
Diagnosis and Treatment Options in Pigmented Villonodular Synovitis of the Knee: A Narrative Review.
Fazio A, Mazzella GG, Greco T, et al.
Journal of clinical medicine 2025; (14(16)) doi:10.3390/jcm14165857.
PMID: 40869683 - 8
A Case Report of Diffuse-type Tenosynovial Giant Cell Tumor as a Calcaneus Mass: A Diagnostic Challenge.
Wang Z, Wang X, Zhang S
Current medical imaging 2024; (20()):e15734056286012 doi:10.2174/0115734056286012240111093147.
PMID: 38454770 - 9
Combined Arthroscopic and Endoscopic Synovectomy for Diffuse Pigmented Villonodular Synovitis (PVNS) of the Ankle.
Lui TH, Leung YT
Arthroscopy techniques 2022; (11(11)):e2039-e2047 doi:10.1016/j.eats.2022.08.001.
PMID: 36457390 - 10
Optimal Treatment for Tenosynovial Giant Cell Tumor of the Hand.
Kitagawa Y, Takai S
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 2020; (87(4)):184-190 doi:10.1272/jnms.JNMS.2020_87-408.
PMID: 32350187 - 11
Satisfactory functional outcomes and low recurrence rates at a mean 10-year follow-up after combined staged synovectomy and external radiotherapy for diffuse pigmented villonodular synovitis of the knee.
Fahmy FS, ElAttar M, Farhan AH, et al.
Journal of ISAKOS : joint disorders & orthopaedic sports medicine 2025; (13()):100907 doi:10.1016/j.jisako.2025.100907.
PMID: 40419142 - 12
Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.
Gelderblom H, Wagner AJ, Tap WD, et al.
Cancer 2021; (127(6)):884-893 doi:10.1002/cncr.33312.
PMID: 33197285
This page provides educational information about surgical options for TGCT. It is not a substitute for professional medical advice; always consult your orthopedic oncologist for personalized treatment planning.
Get notified when new evidence is published on Tenosynovial giant cell tumor.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.